Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma
Elaine T. Lam*, Michael K K Wong, Neeraj Agarwal, Bruce G. Redman, Theodore Logan, Dexiang Gao, Thomas W. Flaig, Karl Lewis, Jamie Poust, Paul Monk, Anthony Jarkowski, Arun Sendilnathan, Marcus Bolden, Timothy M. Kuzel, Thomas Olencki
Dive into the research topics of 'Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.